Article: Photodynamic cell therapy may help prevent graft-versus-host disease.

2002 MAY 30 - (NewsRx.com & NewsRx.net) -- Collaborators of Celmed BioSciences, a subsidiary of Theratechnologies, published groundbreaking results in the May 1, 2002, issue of Blood, the journal of the American Society of Hematology (ASH).

The study suggests that a photodynamic cell therapy process (PDT) can selectively deplete host alloantigen-specific T cells to prevent graft-versus-host disease (GvHD), while preserving immune and antileukemia functions.

The research was conducted by researchers from the bone marrow transplantation program at Duke University Medical Center in Durham, North Carolina.

The researchers demonstrated in a mouse ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!